26 stories mentioning PFE
Every FINWIRES story that references PFE, newest first.
Pfizer (PFE) has an average rating of hold and mean price target of $28.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $26.60, Change: $-0.20, Percent Change: -0.73%
Pfizer (PFE) said Tuesday it entered into settlement agreements with three generic drug manufacturers regarding lawsuits filed in the US District Court for the District of Delaware for patent infringement related to Vyndamax, a cardiomyopathy transthyretin-mediated amyloidosis treatment.The settlements extend the drug's effective US patent expiry date to June 1, 2031, subject to the outcome of other litigation, the company said."Pfizer had previously anticipated a significant decline in U.S. revenues for Vyndamax beginning in 2029 upon patent expiry," Pfizer said. "As a result of this settlement, revenues are now expected to remain relatively stable from 2028 through mid-2031."Price: $26.65, Change: $-0.15, Percent Change: -0.54%
Pfizer Reaches Three Settlements in Vyndamax Patent Infringement Suits
Pfizer's (PFE) tafamidis bench trial commencing next week shows an asymmetric upside based on modeling of three core outcome scenarios, creating a $5 billion net present value differential between bear and bull cases, RBC Capital Markets said in a Monday note.The investment firm said the lawsuit hinges on the '441 polymorph patent that is set to expire in 2035 and is "scientifically the weakest," as the '695 compound and '696 method-of-use patents are expected to hold.RBC estimated a 19% probability for a Pfizer win, with the company showing infringement and getting protection through 2035, representing over $6 billion in net present value.There is a 60% probability for a tie, with generics entry from around 2032, representing net present value of over $3 billion, according to the note.Additionally, there's a 21% probability for Pfizer losing the case and its polymorph patent is held as not infringed, translating into 2028 entry of generics, which is currently priced in the company's stock, the firm said.RBC maintained its underperform rating on the stock with a $25 price target.Price: $27.77, Change: $+0.21, Percent Change: +0.74%
Pfizer (PFE) has an average rating of hold and mean price target of $28.94, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Pfizer (PFE) has an average rating of hold and mean price target of $28.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $26.90, Change: $-0.02, Percent Change: -0.07%
Showing 21-26 of 26